We believe everyone has the capacity to achieve what was once considered improbable, impossible — or is yet to be imagined. Operating as a bridge between Silicon Valley and exponential technology startups in innovation hubs around the world, Singularity University Ventures is the world’s leading impact investment platform, connecting the people, capital, and ideas that promise to solve humanity’s Global Grand Challenges. Activated by our startup-programs, and circling our 7 international campuses, 18 international summits, 127 chapters in 63 countries, and nearly 200,000 highly-influential alumni, our globally distributed legion of faculty, visionaries, successful entrepreneurs, corporate leaders, domain experts, imagineers, makers, mentors, investors, corporates, NGOs, movers, shakers and policy-makers, provide entrepreneurs with exceptional insight, advice, support, network connections, and force-acceleration. With a portfolio of 60 companies representing cumulative capitalization of over half-a-billion dollars, we are impact investors, seeking to generate a measurable, beneficial social or environmental impact alongside a financial return. We believe that building a better world is the ultimate investment — this is our inspiration, and our mission.

Singularity University Ventures

Viridos develops and commercializes genomic-driven solutions to address global energy and environmental challenges. The company engages in synthesizing and programming DNA in developing and utilizing the technologies in synthetic genomics. It designs and develops microbes for industrial processes and environmental applications. The company also develops microbial cultivation technologies and monitoring approaches that reveal novel microorganisms, suites of new genes, and fermentation platforms for the metabolic engineering of microbes for commercial Bioenergy applications. In addition, it involves in designing advanced biofuels with properties compared to ethanol and biodiesel; harnessing photosynthetic organisms to produce value-added products directly from sunlight and carbon dioxide; developing new biological solutions to enhance production and/or recovery rates of subsurface hydrocarbons; and developing high-yielding, disease resistant, and economic feedstocks. The company's solutions help in improving the production of energy, chemicals, and pharmaceuticals, as well as enabling carbon sequestration and environmental remediation.

Viridos

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.   There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.   In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Celgene

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.

Illumina

The OS Fund finances and supports inventors and scientists who are working on audacious breakthroughs to solve the greatest issues and opportunities facing humanity today. Our mission is to partner with tech pioneers who aim to improve the lives of billions of people around the world for generations to come.  In the same way that computers have operating systems at their core — dictating the way a computer works and serving as a foundation upon which all applications are built — everything in life has an operating system (OS).

OS Fund

Illumina Ventures is an independently managed venture fund in a strategic partnership with Illumina. Illumina provides the majority of their capital and access to the expertise and vision of the world's leading genomics solutions provider. They invest primarily in early stage companies, in areas where their expertise and special relationship with Illumina can add value. They typically syndicate with other leading institutional and strategic investors. Focus areas include applications of genomics in life science research, healthcare, agriculture and environmental science, public safety and personal wellness.

Illumina Ventures

GE Ventures combines capital, technical, and commercial services. They invest in the healthcare and life sciences, energy and mobility, manufacturing and supply chain, enterprise productivity applications, digital infrastructure, and frontier technologies sectors.

GE Ventures

StartUp Health is investing in a global army of Health Transformers to achieve health moonshots. StartUp Health is on a 30-year mission to collaborate with entrepreneurs to improve the health and wellbeing of everyone in the world. Since 2011, StartUp Health has been investing in a global army of entrepreneurs -- called Health Transformers -- to achieve health moonshots: Access to Care, Cost to Zero, Cure Disease, End to Cancer, Women’s Health, Children’s Health, Nutrition and Fitness, Brain Health, Mental Health and Happiness, Addiction, Longevity, and Pandemic Response.   StartUp Health has the world’s largest health innovation portfolio with more than 330 companies across six continents and 26 countries and is backed by leading investors including Advocate Aurora Health, Chiesi, Steve Case, Mark Cuban, Esther Dyson, Brad Feld, GuideWell, Jason Finger, Jerry Levin, Kaiser Permanente, Masimo, Novartis, Otsuka, and Ping An.

StartUp Health

AMINO Capital is a global venture capital firm based in Palo Alto, with investment theme of data moat and network effect.  With over $1 billion in capital under management, Amino has funded hundreds of companies in seed-to-growth stages across Consumer, PLG SaaS, Frontier Tech, and Web3, including 35 successful exits, around 20 unicorns and over 35 companies which are valued over $100M, such as Chime, Webflow, Rippling, Grail, Weee, Replit, Turing, Dfinity, OmiseGo, Oasis Labs, Instawork, Wetravel, AIFI.io, Wyze, Writesonic, D-Matrix and Beacons.ai.

Amino Capital

Threshold is an early-stage venture capital firm that focuses on a high-conviction investment strategy. The firm partners with entrepreneurs to build innovative consumer, enterprise, and healthcare technology companies.

Threshold

Founded in 2000, Emerging Technology Partners (“ETP”) is a life sciences focused investment fund with a cross border investment focus. ETP was founded with a simple mission: to provide capital and assist management in building and commercializing breakthrough diagnostic and therapeutic products in the fields of life sciences, while providing superior returns to their investors. ETP supports their portfolio companies facilitate strategic alliances including cross-border partnerships, recruit management, and acquire new products and technologies to accelerate growth in both US and China. They have investment partners in San Francisco, Boston, Washington DC, and Beijing.

Emerging Technology Partners

Panacea Venture focuses on investing and incubating R&D and innovative companies in the field of life sciences.

Panacea Venture

TVM Capital Healthcare is a highly focused private equity and growth capital firm focusing on making growth capital and buyout investments in companies that are already, or aspire to become, leaders in the healthcare markets of the Middle East and North Africa (MENA), India and Turkey. The firm is headquartered in Dubai with additional offices in Beirut, Munich and Boston.

TVM Capital Healthcare

Human Longevity

Novel therapies to reboot cells and organs

Cell & Gene Therapy

<div>
 
 New Jersey-based Celularity is a biotechnology company that develops biomaterials for degenerative diseases and therapeutics for hematological malignancies, solid tumors, and autoimmune and degenerative diseases. The company utilizes a variety of placenta-based platforms for its different therapeutics, including Natural Killer (NK) Cells, Chimeric Antigen Receptor T-cells, and exosomes. The company was formed in July 2021, when Celularity merged with GX Acquisition Corp in a transaction valued at USD 138 million. Through this merger, the combined entity began operations under the &ldquo;Celularity&rdquo; name and the company began trading on the Nasdaq under the ticker symbol &ldquo;CELU.&rdquo;&nbsp;
 
 
 
 
 As of May 2024, Celularity had developed four five biomaterial solutions for degenerative diseases, with all having received regulatory approval. These include Interfyl (a connective tissue matrix); Biovance (an amniotic membrane allograft); Centaflex (a human placenta tissue matrix); Biovance 3L (a tri-layered amniotic membrane allograft); and Biovance 3L Ocular (a tri-layered amniotic membrane allograft for ocular applications). The company also had four three degenerative disease biomaterial candidates in the discovery stage for tendon, wound coverings, and bone, spine, and dental indications as of the same date. 
 
 
 
 
 Furthermore, as of the same date, Celularity had several candidates in various stages of clinical testing for hematological malignancies: two mesenchymal-like adherent stromal cell (MLASC) based therapeutics for the treatment of Facioscapulohumeral muscular dystrophy (FSHD) and autoimmune and degenerative disease, one hybrid T-Cell and Natural Killer Cell therapeutic for autoimmune disease, one T-Cell therapeutic for solid tumor indications, and one Natural Killer Cell therapeutic for aging-related/Senescence. Its MLASC therapeutic for FSHD was in Phase I/II of clinical testing.
 
 
 
 
 Key customers and partnerships
 
 
 
 
 In May 2021, Celularity entered a multi-year partnership with software provider Palantir Technologies to accelerate and advance cellular therapy development. Through the partnership, Celularity aimed to use Palantir&rsquo;s Palantir Foundry Platform to create more detailed insights from Celularity&rsquo;s drug discovery, process development, and manufacturing operations.&nbsp;
 
 
 
 
 In November 2021, the company entered a collaboration agreement with immuno-oncology company Imugene. Through the agreement, Imugene and Celularity aimed to develop a combination of Imugene&rsquo;s CD19 oncolytic virus technology and Celularity&rsquo;s CD19 targeting allogeneic chimeric antigen receptors for the treatment of solid tumors.
 
 
 
 
 In January 2023, Celularity and international import/export company CH Trading Group partnered with Tamer Group to distribute Celularity&rsquo;s regenerative biomaterial solutions to The Organization of Islamic Cooperation (made up of 57 countries), The Gulf Cooperation Council (made up of six countries), and The African Union (made up of 55 countries).&nbsp;&nbsp;
 
 
 
 
 
 
 
</div>

Longevity Tech

<div>
 
 Sun Genomics is a personalized probiotics company that uses gut microbiome analysis and custom formulations to improve health outcomes.
 
 
 
 
 Sun Genomics has its in-house CLIA lab, where it uses whole-genome sequencing technology, with a patented bioinformatic pipeline to interpret the trillions of microbes in a user&rsquo;s gut. Calprotectin is a specific test to look at the level of the protein calprotectin in the gut, which aids in diagnosing IBD. The GI Pathogen Test looks at specific harmful strains and is a separate test from the microbiome test.
 
 
 
 
 The process analyzes gut composition and records where microbes are either in ample or in deficient supply. Based on the data, the company designs probiotics that are claimed to enhance the health state of the guts.&nbsp;
 
 
 
 
 Its product, Flor&eacute;, is available in capsules and powder andare catered differently to various age categories. It also offers dietary complements, such as multivitamins.&nbsp;
 
 
 
 
 Custom-formulated probiotics are claimed to help with abdominal pain, constipation, bloating, SIBO, leaky gut, and other digestive issues. The company also claims that the products are 100% natural, vegan (optional), gluten-free, non-GMO, and free of artificial preservatives.
 
 
 
 
 Flor&eacute; claims to have built the largest longitudinal whole-genome microbiome dataset in the world, which includes data on over 23,000 organisms, such as bacteria, parasites, yeast, viruses, phages, and fungi.
 
 
 
 
 Key customers and partnerships
 
 
 
 
 Flor&eacute; partnered with the Swiss Integrative Center for Human Health in December 2021 to expand product offerings to the EU by setting up an international office in Switzerland.&nbsp;
 
 
 
 
 In January 2023, Flor&eacute; by Sun Genomics partnered with Royal DSM (health, nutrition, and bioscience investment firm), whose investment unit, DSM Venturing, made an investment in Flor&eacute;. The companies matched during the MassChallenge Switzerland Sustainable Food Solutions Challenge, and together, they expected to collaborate on research, including DSM&rsquo;s use of Flor&eacute;&rsquo;s algorithms to gain insight into novel ingredients. In return, DSM was to help Flor&eacute; source high-quality ingredients for its products and take advantage of DSM&rsquo;s deep knowledge base and extensive business network.
 
 
 
 
 Funding and financials
 
 
 
 
 In June 2020, the company raised USD 8.7 million in a Series A funding round led by Pangaea Ventures. The company expected to use the funds to support its growth in the custom probiotics market, scale delivery across the US, enter international markets, and propel the publication of its studies with leading academic institutions.
 
 
 
 
 
</div>

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink.   Floré Clinical, which is specifically for professional practitioners and their patients.   Floré Defense, Balance, and Performance for sports teams and athletes.

Solius is a new technology to help vitamin D deficient Canadian for human health. The company is designed to harness the healing powers of the sun to stimulate the production of vitamin D without the harmful UVA rays or issues related to supplements. They provide the benefits of the sun without the harmful rays to unlock the healing powers of the human body, improving physical, mental, and immune function. Solius stimulates the body’s production of hormones and peptides critical to many aspects of health and wellbeing. Every element of SOLIUS has been designed to enhance the user experience and set a new standard for medical devices everywhere. Solius also developed an ultraviolet light system to help treat COVID-19. Solius was founded in 2011 and is headquartered in Bainbridge Island, Washington, United States.

Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

OxStem plans to develop small molecule drugs that can activate repair mechanisms that already exist within the body. Building on decades of experience in medicinal chemistry, OxStem will design drugs that can programme resident stem and stem-like cells in situ to treat currently untreatable age-related conditions.

Human Longevity (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. Its business areas include the HLI Health Nucleus, a genomic powered clinical research center that uses whole-genome sequence analysis, advanced clinical imaging, and innovative machine learning, along with curated personal health information to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology.  It was founded in 2013 and is headquartered in San Diego, California.

<div>Human Longevity is a genomic-based, health intelligence company that aims to build a comprehensive database on human phenotypes and genotypes and uses advanced AI, ML, and genome sequence analysis to develop new methodologies and therapeutics to treat age-related diseases.</div>

Human Longevity Completes Upsized $39.8M Series B Financing

Flore by Sun Genomics

Pangaea Ventures

SOSV

Danone Manifesto Venture

Nascita Ventures

Diagnostic tests and services focused on assessing the health of an individual's gut microbiome and their metabolic processes to identify internal age-related issues

Solius

<div>
 
 Human Longevity is a genomic-based, health intelligence company that aims to build a comprehensive database on human phenotypes and genotypes and uses advanced AI, ML, and genome sequence analysis to develop new methodologies and therapeutics to treat age-related diseases.
 
 
 
 
 The company&rsquo;s 100+ program is a proprietary program that combines technology with medical professionals to help improve users&rsquo; health spans. Clients receive annual precision health assessments informed by genomics, blood biomarkers, and in-depth imaging. The clinicians and other professionals provide pre-symptomatic diagnoses and treatments based on these data and continuously track health progress.
 
 
 
 
 With around 2,000 members in its headquarters in San Diego as of October 2023, the company has opened two more sites in San Francisco and Beijing. As of October 2023, the company reported plans to open seven other locations around the world over the following five years.
 
 
 
 
 
</div>

Mitrix Bio addresses mitochondrial dysfunction by developing bioreactor-grown mitochondria to be transplanted into the human body to regenerate organs, reverse age-related disease, and support other longevity therapies. Large-scale mitochondrial transfusion could potentially treat Alzheimer's, Parkinson's, AMD, glaucoma, infectious disease, and other age-related diseases, along with children's mitochondrial mutation diseases. The company believes that the same technique can be used in healing and reducing frailty for the aged, speeding healing of wounded soldiers, or combating aging itself. The company is developing technologies and infrastructure targeting to reverse mitochondrial mtDNA degeneration targeting parts of the body that most commonly experience mitochondrial dysfunction. The company has six programs at preclinical stages in its pipeline (as of October 2023). These programs are focused on immunology (infectious diseases), neurology (Alzheimer's/Parkinson’s), ophthalmology (AMD/glaucoma), dermatology (aking aging/wound healing), musculo-skeletal (sarcopenia, frailty), and organs (liver/kidney).

Mitrix Bio

Sierra Sciences engages in research to develop therapeutics targeting aging based on telomeres. These get shorter as people age and lead to various diseases. The company aims to extend the human lifespan and healthspan based on addressing telomere shortening as a solution to address effects of human aging. The company receives royalties from the sale of Product B, a nutraceutical supplement developed in a partnership and distributed through Isagenix. The company develops therapeutics focused on pharmaceuticals to slow and reverse the aging process, nutraceuticals to slow and reverse aging, telomere protection, telomere length measurement, cancer diagnostics, cancer treatments, telomerase gene therapy, immortal pet cloning, and human growth hormones.

Sierra Sciences

Turn.bio is a biotech company developing therapies based on epigenetic reprogramming and reverse cellular aging. The company develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. This is focused on reprogramming the epigenome to restore capabilities that are often lost with age. Its proprietary ERA Platform can reportedly be used to revitalize different cells throughout the body. The company is exploring its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis, and ophthalmology. The platform is claimed to enable control of the time, duration, and dosage of transcription factors to optimize the mRNA cocktail for each indication. This reportedly allows control of reprogramming, moving the epigenome to a more youthful state step-by-step by carefully pulsing the cell with the transcription factors. The company claims to have discovered that the use of quiescent stem cells can significantly help to repair or replace specific types of damaged tissue. In these cases, the company reportedly deploys its Artificial Niche (AN) technology to protect the stem cells. AN technology combines stem-cell biology with biomolecular materials engineering and micro-fabrication technologies to generate novel cell-culture platforms that mimic crucial biochemical or structural aspects of the niche. turn.bio’s novel eTurna Platform can reportedly deliver a variety of cargoes requiring different routes of administration and be fine-tuned and targeted to specific tissue and cells. Funding and financials In July 2022, biotech company VitaDAO made a USD 1,000,000 investment into turn.bio. The investment was intended to fund turn.bio’s preclinical efficacy testing phase for mRNA therapeutics for dermatological and ophthalmological longevity research.

Turn.bio

<div>
 
 AgeX Therapeutics is a biotech company engaged in the development and commercialization of novel therapeutics focused on aging.&nbsp;
 
 
 
 
 The company is building upon the foundation of its proprietary technologies, such as PureStem and induced Tissue Regeneration, to develop medicines targeting aging and related diseases. Through PureStem, the company claims to have the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging. iTM is claimed to be the company's longevity platform intending to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.
 
 
 
 
 Its product pipeline includes two cell-based and two iTR-based product candidates in development: AGEX-BAT1 and AGEX-VASC1.
 
 
 AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders, such as type 2 (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy in the discovery stage of development, composed of young regenerative vascular-forming cells.&nbsp;
 
 
 
 
 The company was founded by leading gerontologist, bioentrepreneur, and Ph.D. holder Dr. Michael D. West,&nbsp; a highly-regarded pioneer in cellular aging, stem cell research, telomerase, and cloning.
 
 
 
 
 In August 2023, the company entered a merger agreement with Serina Therapeutics, a privately held, clinical-stage biotech company developing a pipeline of therapies for the treatment of Parkinson&rsquo;s disease and other neurological diseases. Under this, Serina merged with a wholly-owned subsidiary of AgeX therapeutics in an all-stock transaction. The combined company continues under the &ldquo;Serina Therapeutics&rdquo; name and focuses on advancing Serina&rsquo;s pipeline of small-molecule drug candidates targeting central nervous systems indications.
 
 
 
 
 Funding and financials
 
 
 
 
 The company recorded total revenue of USD 34 million in 2022, compared to USD 144 million in 2021 (77% decrease). This is due to absence of grant revenues in 2022, as opposed to 2021, where grant revenue was USD 104 million. Net loss reported for 2022 was USD 10.5 million, compared to the loss of USD 8.7 million recorded in the preceding year.
 
 
 
 
 
</div>

AgeX Therapeutics

<div>
 
 UNITY Biotechnology develops therapeutics targeting age-related diseases, particularly focusing on therapy in ophthalmologic diseases, including diabetic macular edema and age-related neurologic conditions.
 
 
 
 
 Its therapeutics are intended to selectively eliminate or modulate senescent cells to slow down, stop, or even reverse age-related disease and restore aging or damaged tissue to a more functionally healthy state. The approach is expected to remedy diseases of aging, such as retinopathies, neurodegenerative disorders, fibrosis, and cancer.&nbsp;
 
 
 
 
 The company&rsquo;s lead drug candidate, UBX1325, is evaluated for the treatment of age-related diseases of the eye, including diabetic macular edema. The small molecule targets Bcl-xL, a protein that senescent cells rely on for survival. It is claimed that UBX1325 demonstrated a statistically significant and clinically meaningful improvement in mean best corrected visual acuity (BCVA) across 48 weeks compared to sham treatment in the Phase II BEHOLD study in patients with DME. A Phase IIb study (ASPIRE) was enrolling patients with DME to evaluate UBX1325 head-to-head against aflibercept.
 
 
 
 
 UNITY Biotechnology was also developing programs targeting the Tie2 signaling pathway for therapeutic benefit. Tie2 pathway activity declines with age and causes the loss of vascular barrier integrity and diseased blood vessel formation in the eye. The Tie2/VEGF bispecific molecule targets two pathways believed to be core to disease progression in DME and AMD. Another program directed at Tie2 activation is in preclinical studies for multiple indications.
 
 
 
 
 The company's neurology programs intend to explore new mechanisms for cognitive benefit, and the company licensed its &alpha;-Klotho program, UBX2089, to Jocasta Neuroscience for development and commercialization in cognitive dysfunction associated with neurological and psychiatric conditions.
 
 
 
 
 
</div>

UNITY Biotechnology

Companies conducting R&D on cell and gene therapies that aim to repair or replace dysfunctional cells to address the root cause of age-related diseases

Companies involved in the development of novel small molecules or chemical drugs that target specific proteins or pathways in the body to treat age-related diseases as well as the identification of existing drugs that can be repurposed for the treatment of such diseases

Platforms and tools that collect and analyze patient data to detect, prevent, and monitor age-related damage

Dietary supplements and wellness products that are developed through scientific approaches to slow down age-related damage

Companies developing therapies for age-related sensory deficiencies such as vision and hearing loss

Companies in the neurotechnology sector that develop tools such as neuroimaging and neurostimulation devices; pharmaceutical drugs and therapies aimed at treating age-related neurological conditions

Platforms and tools that provide personalized remedies for general well-being and to mitigate the risk of age-related diseases

Genomics is used for diagnostics and to offer tailored treatment for age-related diseases

Offers digital platforms and devices that allow individuals to measure, track, and potentially modify the physiological changes associated with aging

AL/ML is used in drug discovery and development as well as diagnostic tools to support longevity-related treatments

<div>
 
 Human Longevity (HLI), a genomic-based health intelligence company, secured USD 39.8 million in a Series B funding round. The round was led by TVM Capital healthcare, and saw participation from Panacea Venture and Emerging Technology Partners. This has elevated the company's total funds to USD 380.3 million.
 HLI intends to use the new funds to invest in its AI health risk and recommendation platform, in addition to new longevity-related technologies and services. The company also plans to put the funds towards new expansion sites globally.
 
</div>

Human Longevity

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless